Erasca Shares Drop 48% After Patient Death in Early Cancer Drug Trial
Erasca (ERAS) shares fell 48% following the disclosure of a patient death in its Phase 1 ERAS-0015 trial, raising concerns about the safety of its cancer drug. The company's stock closed at $9.90, and trading volume surged to 51 million shares, far above its three-month average. The incident has sparked mixed reactions from analysts, with some suggesting the death may be a one-off case rather than a drug-related issue.
Topics: biotech clinical trial patient death pharmaceuticals stock price drop